Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23276| Title: | Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology. | Austin Authors: | Pearce, Samuel;Maingard, Julian T;Li, Kenny;Kok, Hong Kuan;Barras, Christen D;Russell, Jeremy H ;Hirsch, Joshua A;Chandra, Ronil V;Jhamb, Ash;Thijs, Vincent N ;Brooks, Duncan Mark ;Asadi, Hamed | Affiliation: | Department of Neurosurgery, Austin Health, Heidelberg, Victoria, Australia Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Austin Health, Heidelberg, Victoria, Australia Interventional Neuroradiology Service, Department of Radiology, Austin Health, Heidelberg, Victoria, Australia Interventional Neuroradiology, St Vincent's Hospital, Melbourne, Victoria, Australia Interventional Neuroradiology Unit, Monash Imaging, Monash Health, Melbourne, Victoria, Australia School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia Interventional Radiology Service, Department of Radiology, Northern Hospital, Melbourne, Victoria, Australia South Australian Institute of Health and Medical Research, Adelaide, South Australia, Australia School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia Department of Imaging, Monash University, Melbourne, Victoria, Australia Stroke Division, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia School of Medicine, University of Melbourne, Melbourne, Victoria, Australia |
Issue Date: | Sep-2020 | Date: | 2020-05-18 | Publication information: | Clinical Neuroradiology 2020; 30(3): 425-433 | Abstract: | The development of endovascular treatment for intracranial aneurysms has established new techniques such as balloon and stent-assistance, flow diversion and endosaccular occlusion devices. Antiplatelet treatment is an important aspect to reduce risk of thrombus formation on microcatheters and implanted devices when utilizing these methods. It is particularly relevant for flow diverting stents to prevent early and late stent thrombosis. Consideration of platelet physiology and appropriate selection of antiplatelet medication is important as platelet dysfunction drives many of the pathological processes and complications of neurointerventional procedures. Part one of this review focuses on basic platelet physiology, pharmacology of common antiplatelet medications and future directions and therapies. Part two focuses on clinical applications and evidence-based therapeutic regimens. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23276 | DOI: | 10.1007/s00062-020-00910-5 | ORCID: | 0000-0003-3692-120X 0000-0002-6614-8417 0000-0001-5034-570X 0000-0003-2475-9727 |
Journal: | Clinical Neuroradiology | PubMed URL: | 32424668 | Type: | Journal Article | Subjects: | Aneurysm Coiling Flow diverting Intracranial Stent |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.